NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation SystemGlobeNewsWire • 4h
NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial PainGlobeNewsWire • Tuesday
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research ProgramGlobeNewsWire • 10/22/26
NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing TechnologyGlobeNewsWire • 10/08/26
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase OrderGlobeNewsWire • 10/05/26
NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution AgreementGlobeNewsWire • 09/17/26
NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call TranscriptSeeking Alpha • 08/13/26
NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call TranscriptSeeking Alpha • 05/12/26
NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications TranscriptSeeking Alpha • 03/12/26
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call TranscriptSeeking Alpha • 02/17/26
NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call TranscriptSeeking Alpha • 12/17/25
NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025GlobeNewsWire • 09/08/25
NMTC Stock Gains as FDA Clears OneRF System for Facial Pain TreatmentZacks Investment Research • 08/19/25
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial PainGlobeNewsWire • 08/18/25
NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call TranscriptSeeking Alpha • 08/14/25
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%GlobeNewsWire • 08/14/25
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - UpdateGlobeNewsWire • 07/31/25
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern TimeGlobeNewsWire • 07/31/25
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark OfficeGlobeNewsWire • 07/23/25
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation SystemGlobeNewsWire • 06/23/25
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate SecretaryGlobeNewsWire • 06/03/25
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025GlobeNewsWire • 05/29/25